

# Nadecnemab Biosimilar - Research Grade

**Product Code:** ICH5260

**More Information**

**Species Reactivity:** Human

**Target:** GFRA3

**Concentration:** >1mg/ml

**Isotype:** Human IgG4 - kappa

**Host:** CHO Cells

**product name H2:** Nadecnemab Biosimilar - Research Grade

**Sequence:** <https://www.imgt.org/mAb-DB/>

**Buffer:** ICH3002

**UniProt:** O60609

**Shipping Conditions:** Blue ice

**background:** This product is an unconjugated, non-therapeutic recombinant analog of nadecnemab, supplied for research use only and built around the target GFRA3 (GDNF family receptor alpha-3). It is a human IgG4-kappa molecule that reproduces the antigen-binding specificity of the originator anti-GFRA3 antibody, allowing laboratories to interrogate GFRA3 biology and the artemin/RET signaling axis without sourcing clinical material. It is not the clinical drug and is not intended for human or veterinary use. The preparation is offered at research-grade low endotoxin (typically under 1 EU/mg, with ultra-low-endotoxin options under 0.5 EU/mg) and in bulk milligram-to-gram quantities, making it well suited to reproducible assay development and scale-up. Typical research applications include use as a binding and specificity reference standard, as an isotype-matched positive control in GFRA3 detection or neutralization workflows, as a benchmark antibody for

mechanism-of-action and epitope studies, and as a tool for antibody-engineering and ADC or ADCC development pipelines. The IgG4 backbone confers minimal effector recruitment, which is useful when a predominantly ligand- or receptor-blocking readout is desired.

GFRA3 (GDNF family receptor alpha-3; UniProt O60609) is a glycosylphosphatidylinositol (GPI)-anchored cell-surface co-receptor and a member of the GDNF-family receptor alpha (GFRalpha) family. It is the preferred ligand-binding co-receptor for artemin (ARTN), one of the four GDNF-family ligands. Upon binding ARTN, GFRA3 recruits and drives autophosphorylation and activation of the RET receptor tyrosine kinase, engaging downstream cascades including RAS-MAPK (ERK), PI3K-AKT, and Src signaling. This ARTN-GFRA3-RET axis supports the development, survival, and maintenance of subsets of peripheral sensory and sympathetic neurons, and its expression is largely restricted to specific neuronal and neural-crest-derived populations. Because of its role in nociceptor sensitization and its comparatively selective tissue distribution, GFRA3 has attracted interest as a target in pain and in artemin-associated processes.

**Other names:** GDNF receptor alpha-3, GDNFR-alpha-3, GFR-alpha-3, GDNF family receptor alpha-3

**Specificity:** Detects human GFRA3

**Purification Method:** This monoclonal antibody was purified using Protein A

**Formulation:** Sterile, preservative-free, solution in PBS. BSA and Azide free.

**Purity:** >95% by SDS-PAGE

**Endotoxin:**  $\leq 1.0$  EU/mg as determined by the LAL method

**Storage:** This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

**Applications:** Functional Assays

**Application Notes:** This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

**Use:** Products are for research use only. Not for use in diagnostic or therapeutic procedures.

**Delivery Time:** 4 weeks